Delavirdine

DB00705ApprovedInvestigationalWithdrawnSmall moleculeHuman Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor Nonnucleoside Reverse Transcriptase Inhibitors

Delavirdine is a non-nucleoside reverse transcriptase inhibitor used to treat HIV infection.

Mechanism: Delavirdine binds directly to viral reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by disrupting the enzyme's catalytic site.
Curator reviewed
Primary indication: For the treatment of HIV-1 infection in combination with appropriate antiretroviral agents when therapy is warrantedCurator reviewed · 1 structured indication
Formula / weight: C₂₂H₂₈N₆O₃S · 456.561 g/mol (avg)
First approval: Canada, 2009 · United States, 1997
Code names: U 90152 S

Resolves to

Compound

UNIIDOL5F9JD3ECAS136817-59-9ChEMBLCHEMBL593ChEBI119573PubChem5625KEGGC06941

Clinical / RWD

RxNorm83816ATCJ05AG02PharmGKBPA449223

Structure

InChIKeyWHBIGIKBNXZKFE-UHFFFAOYSA-NSMILESCC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2

Targets

Q72547polP03366gag-pol

What you can answer from here — as of October 01, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1,101Drug interactionsStructured to mechanism, not free text

9Clinical trialsPhase, status and sponsor resolved per trial

1Structured indicationCondition, population, route and combination as fields, not prose

11ContraindicationsEach with its own population and attribute set

7Marketed productsAcross 2 countries and 4 labellers

1ATC codeIncluding every combination product, plus 35 drug categories

24+ReferencesStructured and connected to the statements they support

Which drugs share a target with Delavirdine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In